Glaxo, Watson Strike $35M Deal Over Wellbutrin
Watson Pharmaceuticals Inc. and GlaxoSmithKline have struck a deal that will resolve a patent suit brought in 2005 over the extended release version of the blockbuster depression treatment Wellbutrin XL....To view the full article, register now.
Already a subscriber? Click here to view full article